Dabigatran lowers risk of liver injury in AF patients
Use of nonvitamin K antagonist oral anticoagulants (NOACs), particularly dabigatran, is associated with a significantly reduced risk of laboratory-based liver injury among patients with atrial fibrillation (AF) when compared with warfarin, results of a recent study have shown.
